tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

H.C. Wainwright sees ‘impressive’ commercial data for Iovance’s Amtagvi

H.C. Wainwright reiterates a Buy rating on Iovance Biotherapeutics (IOVA) with a $20 price target after the company announced real-world, retrospective data from patients treated with commercial Amtagvi. The drug demonstrated “impressive” clinical responses, particularly in earlier stage patients, the analyst tells investors in a research note. The firm points out that among 41 evaluable patients treated at four authorized treatment centers, the physician-assessed objective response rate was 48.8%. It believes Amtagvi is working as intended, and even exceeding expectations in less heavily treated patients, post commercialization.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1